Hyderabad News Desk

DelveInsight Business Research LLP

DelveInsight’s ‘Onychomycosis Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of onychomycosis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan and China.

Key Highlights 

• Key Companies working on Onychomycosis  Disease include Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, and many others.

• Key Therapies included in the Onychomycosis  Disease market include Itraconazole, Terbinafine,  MOB015B, Terbinafine HCl, and many others 

• The onychomycosis market size was approximately USD 2,900 million in 2021.

Onychomycosis Overview

Onychomycosis is a fungal nail infection that causes discoloration and thickening of the affected nail plate. It was initially caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by non-dermatophyte molds (NDMs) are more prevalent, especially in warmer climates. Onychomycosis caused by dermatophytes is called tinea unguium. The term Onychomycosis encompasses not only dermatophytes but also yeasts and saprophytic mold infections. It can infect both fingernails and toenails, Onychomycosis of the toenail is more prevalent. Onychomycosis is classified into subtypes based on the invasion pattern. Distal subungual onychomycosis (DSO) is the most common subtype and occurs when the fungus invades the distal aspect of the nail plate. In superficial white onychomycosis (SWO), fungi invade the most superficial layers of the nail plate.

Onychomycosis Disease Epidemiology Insights

• The diagnosed prevalence of onychomycosis population in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China was estimated to be close to 121,608,000 cases in 2021.

 Click here to learn more about the Onychomycosis Disease Market Landscape

 The Report Covers the Onychomycosis  Disease Epidemiology Segmented by:

• Onychomycosis prevalent cases 

• Onychomycosis incident cases 

• Onychomycosis treatment cases 

• Onychomycosis diagnosed cases 

Onychomycosis Disease Market Outlook 

There is only one approved therapy for Onychomycosis in the market, namely, PROGLYCEM (diazoxide) – a non-diuretic benzothiadiazine derivative used for the management of symptomatic hypoglycemia. Proglycem capsules and suspension are manufactured by IVAX Pharmaceuticals and Teva Pharmaceuticals, respectively; the suspension was manufactured for Gate Pharmaceuticals, a division of Teva Pharmaceuticals.

A number of children with Onychomycosis are partially or completely unresponsive to diazoxide. Second-line treatment with other agents such as octreotide/lanreotide, is required in such children. Somatostatin receptor analogs (SSRAs), typically octreotide/lanreotide, which inhibit insulin release, are preferred as second-line treatment in diazoxide-unresponsive patients. The use of SSRAs is off-label as only diazoxide is approved for CHI. Octreotide reduces insulin release by decreasing the insulin gene promoter activity, inhibiting voltage-dependent calcium channels and adenylyl cyclase activity. Long‐acting SSRAs are favored by families on account of the monthly injection regimen without recourse to daily injections as needed for octreotide therapy. One problem with using a long‐acting SSRA is the inability to reduce the dose, unlike with oral preparations such as diazoxide. Given that severity of CHI may naturally reduce over time, the use of fixed‐dose long‐acting SSRAs may be considered disproportionate.

According to DelveInsight, the Onychomycosis (CHI) market in 7MM is expected to witness a major change in the study period 2019–2032.

 Key Companies Working in the Onychomycosis Market

• Moberg Pharma

• Blueberry Therapeutics

• Hallux, 

• Pfizer

• Bausch Health  

And many others.

Onychomycosis Therapies Covered and Analyzed in the Report

• Itraconazole 

• Terbinafine

• MOB015B

• Terbinafine HCl, 

And many others 

Learn more about the Key Companies and Emerging Therapies in the Onychomycosis Disease Market

 Table of Contents 

1.  Key Insights 

2.  Onychomycosis  Disease  Introduction 

3.  Executive Summary of Onychomycosis  Disease            

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Onychomycosis  Disease  Emerging Therapies

7.  Onychomycosis  Disease  Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Onychomycosis Disease Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services